

CITATION REPORT

List of articles citing

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine

DOI: 10.4155/bio.13.72
Bioanalysis, 2013, 5, 1025-40.

Source: <https://exaly.com/paper-pdf/56787769/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. <i>Regulatory Toxicology and Pharmacology</i> , 2013 , 67, 382-91	3.4	32
50	Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. <i>Toxicology and Applied Pharmacology</i> , 2013 , 273, 298-313	4.6	137
49	Bioanalysis special focus issue on antibody-drug conjugates. <i>Bioanalysis</i> , 2013 , 5, 981-3	2.1	17
48	Site-specific antibody drug conjugates for cancer therapy. <i>MAbs</i> , 2014 , 6, 34-45	6.6	449
47	The next generation of antibody drug conjugates. <i>Seminars in Oncology</i> , 2014 , 41, 637-52	5.5	44
46	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 399-410	3.5	59
45	Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker. <i>Cancer Informatics</i> , 2014 , 13, 179-86	2.4	6
44	Clinical pharmacology and assay consideration for characterizing pharmacokinetics and understanding efficacy and safety of antibody drug conjugates. 2015 , 36-55		3
43	Analytical assays for antibody drug conjugate selection and development. 2015 , 56-68		
42	Bioanalytical Assay for Characterization of Antibody-Drug Conjugates (ADCs). <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 , 97-115	0.5	1
41	Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. <i>Protein Science</i> , 2015 , 24, 1210-23	6.3	97
40	Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability. <i>Pharmaceutical Research</i> , 2015 , 32, 3541-71	4.5	46
39	Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 ,	0.5	6
38	Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays. <i>Bioanalysis</i> , 2015 , 7, 1605-17	2.1	20
37	Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1583-604	2.1	26
36	A Bioinformatics Method for the Production of Antibody-Drug Conjugates Through Site-Specific Cysteine Conjugation. 2016 ,		
35	An Overall Comparison of Small Molecules and Large Biologics in ADME Testing. <i>ADMET and DMPK</i> , 2016 , 4, 1	1.3	20

34	Techniques for quantitative LC-MS/MS analysis of protein therapeutics: advances in enzyme digestion and immunocapture. <i>Bioanalysis</i> , 2016 , 8, 847-56	2.1	27
33	Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. <i>Bioanalysis</i> , 2016 , 8, 1383-401	2.1	24
32	A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 407-14	2.8	8
31	Antibody Drug Conjugates for Cancer Therapy. <i>Pharmacological Reviews</i> , 2016 , 68, 3-19	22.5	238
30	LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 137, 170-177	3.5	10
29	Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development. 2017 , 183-201		1
28	The Application of Immunoaffinity-Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics. 2017 , 67-89		
27	Strategies and challenges for the next generation of antibody-drug conjugates. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 315-337	64.1	1068
26	A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1069-1080	6.2	10
25	Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1079-1090	3.5	10
24	Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1147-1159	3.5	7
23	Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with \geq HER2-targeted regimens. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2767-2777	3.8	14
22	Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. <i>Marine Drugs</i> , 2017 , 15,	6	9
21	Process Development and Manufacturing of Antibody-Drug Conjugates. 2018 , 813-836		0
20	Bioconjugation with Maleimides: A Useful Tool for Chemical Biology. <i>Chemistry - A European Journal</i> , 2019 , 25, 43-59	4.8	165
19	Dissociative Bioorthogonal Reactions. <i>ChemBioChem</i> , 2019 , 20, 1615-1627	3.8	36
18	Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 358-376	8.9	9
17	Bioanalytical Challenges in Support of Complex Modalities of Antibody-Based Therapeutics. <i>AAPS Journal</i> , 2020 , 22, 130	3.7	7

16	Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1079-1088	5.9	6
15	A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy. <i>Medicine (United States)</i> , 2020 , 99, e22886	1.8	0
14	Simple and Rapid LC-MS/MS Methods for Quantifying Catabolites of Antibody-Drug Conjugates with SMCC Linker. <i>Journal of Chromatographic Science</i> , 2021 , 59, 642-649	1.4	
13	Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. <i>Bioanalysis</i> , 2021 , 13, 101-113	2.1	2
12	The role of ligand-binding assay and LC-MS in the bioanalysis of complex protein and oligonucleotide therapeutics. <i>Bioanalysis</i> , 2021 , 13, 931-954	2.1	2
11	Mass Spectrometry of Antibody-Drug Conjugates in Plasma and Tissue in Drug Development. 2013 , 279-304		7
10	Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 , 117-131	0.5	1
9	Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. <i>Journal of Pharmaceutical Analysis</i> , 2020 , 10, 209-220	14	18
8	Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	3
7	Investigating the Nonclinical ADME and PK/PD of an Antibody-Drug Conjugate: A Case Study of Ado-Trastuzumab Emtansine (T-DM1). 1-11		
6	Novel methods to characterize antibody-drug conjugates (DAR and PK emphasis). 2015 , 70-88		
5	A regulatory perspective: analytical component of submission packages. 2015 , 90-99		
4	Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.. <i>Antibody Therapeutics</i> , 2022 , 5, 18-29	5.8	2
3	Research Progress of Conjugated Nanomedicine for Cancer Treatment. 2022 , 14, 1522		1
2	A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine aminopeptidase.		1
1	Implementation of Systematic Bioanalysis of Antibody-Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats. 2023 , 15, 756		0